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O B J E C T I V E S The aim of this work was to characterize patterns of late gadolinium enhancement
(LGE) by cardiovascular magnetic resonance imaging in a hemodialysis population at high risk for
cardiovascular events.
B A C KG ROUND The prevalence and distribution of LGE and its relationship to left ventricular mass
(LVM) and function in this population is unknown.
METHOD S Chronic hemodialysis patients at high risk for cardiovascular events—age 50 years,
diabetes, or known cardiovascular disease—were enrolled prior to concerns regarding nephrogenic
systemic ﬁbrosis. Cardiovascular magnetic resonance imaging was performed in 24 patients (age, 59 
11 years; dialysis, 45  38 months) and included steady-state free precession cine imaging and late
gadolinium-enhanced, phase-sensitive, inversion-recovery gradient echo images. Left ventricular mass,
volumes, and function were calculated and indexed to body surface area. A 16-segment analysis was
performed to calculate percentage of LGE, LV wall thickness, and percentage of wall thickening.
R E S U L T S Left ventricular ejection fraction was 48  15%, and the LV mass index was 100  52
g/m2. Late gadolinium enhancement was observed in 79% (19 of 24) of patients in 3 distinct patterns:
infarct-related (32%, 6 of 19), diffuse (37%, 7 of 19), and focal noninfarct (37%, 7 of 19). Late gadolinium
enhancement constituted 15  18% of the LVM and correlated with LVM (r  0.44, p  0.03). A
signiﬁcant, inverse relationship existed between segmental LGE and the percentage of wall thickening
(p  0.0001). Excluding infarct-related segments, as end-diastolic wall thickness increased, so did LGE
(p  0.0001), and as LGE increased, the percentage of wall thickening decreased (p  0.0012). After 23
 3 months of follow-up, 1 patient had developed nephrogenic systemic ﬁbrosis. Seven of the patients
(29%) had developed a hard cardiovascular event, 5 of 19 (26%) with LGE and 2 of 5 (40%) without.
CONC L U S I O N S Late gadolinium enhancement is prevalent in the hemodialysis population and its
extent is related to LVM. Most cases of LGE are not infarct-related and are associated with hypertrophied,
dysfunctional LV segments. Non-infarct-related LGE may signify ﬁbrosis from LV hypertrophy and/or an
inﬁltrative process. Further studies in this patient population will not be possible due to the risk of
nephrogenic systemic ﬁbrosis. (J Am Coll Cardiol Img 2008;1:450–6) © 2008 by the American College
of Cardiology Foundation
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451ccording to the most recent U.S. Renal Data
System report (1), nearly 336,000 Americans
receive dialysis. In this rapidly increasing
population, projected to be over 2 million
atients by 2030, the prognosis is poor with cardio-
ascular disease, specifically sudden cardiac death,
eing the major contributor (2). Many factors may
mpact the susceptibility of the hemodialysis popu-
ation to sudden cardiac death. Comorbidities such
s coronary artery disease (CAD), cardiomyopathy,
nd particularly left ventricular hypertrophy (LVH)
re prevalent, and they are recognized predictors of
ardiovascular events (3,4). Noninvasive identifica-
ion of markers of cardiovascular risk could have
mportant clinical benefits.
See page 457
Although the recent potential linkage between
adolinium contrast agents and nephrogenic sys-
emic fibrosis (NSF) will limit its applicability
5–7), cardiovascular magnetic resonance (CMR)
maging is uniquely suited to characterize myocar-
ial disease in the hemodialysis population. The
MR is a gold standard method for the assessment
f left ventricular mass (LVM) with excellent intra-
nd interobserver reproducibility (8). Unlike echo-
ardiography, CMR measures of LVM are not
onstrained by ventricular loading and are thus
ndependent of hemodialysis sessions (9,10). Using
ate gadolinium enhancement (LGE), CMR has
he ability to reliably detect myocardial fibrosis from
ultiple etiologies (11,12) and is a valuable indica-
or of cardiovascular prognosis (13–16). The objec-
ive of this study was to define the prevalence and
istribution of LGE in a hemodialysis population at
ncreased risk for cardiovascular events.
E T H O D S
ardiovascular magnetic resonance studies were
erformed in consecutive subjects recruited from
he University of Virginia Health System hemodi-
lysis centers with the approval of the local Inves-
igational Review Board, and all participants gave
nformed consent. Inclusion criteria included pa-
ients receiving chronic hemodialysis, defined as
ontinuous hemodialysis for longer than 6 months,
nd the presence of increased risk for cardiovascular
vents. These included age 50 years, diabetes, or
nown cardiovascular disease. A contraindication to
MR was the only criteria for exclusion. Enroll-
ent was conducted from October 28, 2005, to tugust 22, 2006. Enrollment was halted approxi-
ately 4 months before the December 2006 Food
nd Drug Administration warning regarding a pos-
ible relationship between gadolinium chelates and
he development of NSF in patients with kidney
ailure (5,6).
mage acquisition. All CMR exams were performed
n the day prior to a scheduled hemodialysis session.
tudies were performed with an Avanto 1.5-T scan-
er (Siemens Healthcare, Erlangen, Germany) with a
hased array chest coil. After scout imaging, left
entricular function was determined using steady-state
ree precession cine imaging (repetition time, 2.7 ms;
cho time, 1.3 ms; flip angle, 73°; field of view, 300 to
50 mm; and resolution, 1.8  1.4  8.0 mm). Late
adolinium-enhanced imaging was performed 10 to
5 min following an injection of 0.15 mmol/kg
adolinium with a phase-sensitive, inversion-recovery
equence (repetition time, 700 ms; echo time, 4.2 ms;
xed inversion time, 300 ms; flip angle, 25°; field of
iew, 300 to 340 mm; resolution, 1.8  1.3
8 mm). Two different gadolinium-based
ontrast agents were used in the study:
adopentetate dimeglumine (Magnevist,
erlex, Montville, New Jersey) in 20 pa-
ients and gadodiamide (Omniscan, General
lectric Healthcare, Princeton, New Jersey)
n 4 patients. Both the cine and inversion-
ecovery sequences were performed in iden-
ical 2-, 3-, and 4-chamber long-axis views,
s well as sequential short-axis acquisitions
ith a 20% interslice gap.
mage analysis. Dedicated analysis software
Argus, Siemens Healthcare) was used to
alculate LVM, LV volumes, LV function, and LGE.
eft ventricular mass and LV volume measurements
ere indexed to body surface area calculated from the
easured height at the time of CMR and the goal dry
r post-dialysis weight of the patients.
The presence of LGE required increased myo-
ardial signal intensity 2 SD greater than that of
emote myocardium (17,18) in at least 2 imaging
lanes. The signal intensity of enhanced and of
ulled myocardium was determined from each
hort-axis image with LGE present. An American
eart Association 16-segment analysis (excluding
he apex) (19) was performed to calculate the
ercentage of LGE, LV wall thickness, and the
ercentage of wall thickening using the same soft-
are. The total LGE mass was calculated from the
V short-axis images using Argus software. Total
GE and segmental LGE areas were manually
A B B
A N D
CAD
CMR
reson
LGE
enhan
LVH
hyper
LVM
NSF
fibrosraced and then divided by the total LVMR E V I A T I O N S
A C R O N YM S
coronary artery disease
cardiovascular magnetic
ance
late gadolinium
cement
left ventricular
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left ventricular mass
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452egmental LVM, respectively, to calculate total and
egmental percent LGE. The determination of the
GE distribution pattern was made by a reader
ith over 10 years of experience, who was blinded
o clinical data. Infarct-related LGE was deter-
ined by a characteristic subendocardial location in
coronary distribution. A noninfarct pattern of
GE in multiple territories was defined as diffuse
GE. Isolated midwall or subepicardial LGE was
efined as a focal noninfarct LGE pattern.
tatistical analysis. Continuous variables, such as
GE mass, LVM, and hemodialysis duration be-
ween LGE subgroups, were analyzed by analysis of
ariance. Multiple comparisons were adjusted by the
onferroni method. Segmental measurements were
nalyzed using a repeated measures model (20) for the
ffects of end-diastolic and end-systolic thickness and
all thickening (absolute and percentage) to the pro-
ortion of LGE per segment. Analyses were done
sing SAS software (SAS Institute, Cary, North
arolina) version 9.1 “PROC MIXED.” All data are
resented as mean standard deviation and p 0.05
as considered statistically significant.
E S U L T S
atient demographics. Twenty-six patients fulfilled
riteria for enrollment and signed informed con-
ent. One subject withdrew due to obesity and
nother due to claustrophobia. The cohort was 59
11 years of age, 54% male and 79% African
Table 1. Baseline Characteristics for the Study Population and P
All Subjects
(n  24)
Infarct-Relate
(n  6)
Age, yrs 59  11 65  12
Male, n (%) 13 (54) 2 (33)
Comorbid conditions
HTN, n (%) 24 (100) 6 (100)
DM, n (%) 17 (71) 4 (67)
Tobacco use, n (%) 17 (71) 4 (67)
CAD, n (%) 12 (50) 6 (100)
PCI or CABG, n (%) 7 (29) 5 (83)
Stroke, n (%) 4 (17) 1 (17)
Duration of HD, months 45  38 46  40
Etiology of renal disease
DM, n (%) 10 (42) 2 (33)
HTN, n (%) 4 (17) 2 (33)
DM and HTN, n (%) 6 (25) 1 (17)
Cocaine and HTN, n (%) 2 (8) 0
PCKD, n (%) 1 (4) 0
Medicine toxicity, n (%) 1 (4) 1 (17)
CABG  coronary artery bypass graft surgery; CAD  coronary artery disease
gadolinium enhancement; PCI  percutaneous coronary intervention; PCKD  polymerican (Table 1). Diabetes mellitus and hyper-
ension were the primary causes of renal failure:
ither alone or in combination, accounting for 83%
f cases. The average duration of hemodialysis was
5  38 months. X-ray coronary angiography had
een previously performed in 75% (18 of 24) of all
ubjects. Comorbidities were prevalent and con-
isted of hypertension in all subjects, active or
ormer smokers in 71% (17 of 24), diabetes mellitus
n 71% (17 of 24), CAD (defined by a coronary
tenosis  50% on previous X-ray coronary angiog-
aphy) in 50% (12 of 24), a history of percutaneous
oronary intervention or coronary artery bypass
urgery in 29% (7 of 24), and stroke in 17% (4 of
4). One subject with pre-existing NSF was en-
olled prior to the identification of a possible
ssociation with gadolinium chelates. The average
re-dialysis systolic and diastolic blood pressure and
eart rate were 145 30 mm Hg, 75 17 mm Hg,
nd 85  19 beats/min, respectively.
GE. Late gadolinium enhancement was present in
9% of all patients (19 of 24). Subjects with LGE
ould be categorized into 1 of 3 groups based on the
ocation and distribution of LGE (Fig. 1). An
nfarct-related pattern was present in 32% (6 of 19)
f subjects with LGE (Fig. 1A). The diffuse pattern
as demonstrated in 37% (7 of 19) of subjects,
ncluding the patient with pre-existent NSF (Fig.
B). A single subject had LGE consistent with both
n infarct-related and diffuse LGE pattern in dif-
ented by LGE Pattern Subgroups
E Diffuse LGE
(n  7)
Focal Noninfarct LGE
(n  7)
No LGE
(n  5)
59  10 58  15 59  5
5 (71) 5 (71) 2 (40)
7 (100) 7 (100) 5 (100)
4 (57) 5 (71) 4 (80)
6 (86) 5 (71) 3 (60)
3 (43) 2 (29) 2 (40)
2 (29) 1 (14) 0
1 (14) 0 2 (40)
66  54 32  11 28  22
0 5 (71) 3 (60)
1 (14) 1 (14) 1 (20)
4 (57) 0 1 (20)
2 (29) 0 0
0 1 (14) 0
0 0 0
 diabetes mellitus; HD  hemodialysis; HTN  hypertension; LGE  lateres
d LG
; DM
cystic kidney disease.
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453erent locations. The focal noninfarct pattern was
een in 37% (7 of 19) of subjects (Fig. 1C). None of
he subjects in this subgroup had subendocardial
GE. The signal intensity of infarct-related, dif-
use, and focal LGEs were 20  4, 15  8, and 15
6 SD greater than that of nulled myocardium.
Baseline characteristics such as age, the presence
f hypertension, diabetes mellitus, and tobacco
buse for all LGE patterns were similar (Table 1).
ll subjects in the infarct-related LGE pattern
roup and 37% (7 of 19) of the remainder had at
east a single coronary stenosis of 50%.
linical follow-up. Chart review at an average of 23
months following the administration of gadolinium
or this study revealed 1 newly diagnosed case of NSF.
he CMR was performed 30 months after hemodi-
lysis initiation, and the diagnosis was made 16
onths after examination. Magnevist was the gado-
inium chelate used, and a focal, subepicardial pattern
f LGE was present in this subject. The patient had
eceived 2 prior magnetic resonance angiograms (with
ype of gadolinium chelate unknown) at 13 and 21
onths after hemodialysis initiation.
Figure 1. In Chronic Hemodialysis Patients, LGE by CMR Is Pres
Panel A exhibits transmural late gadolinium enhancement (LGE) of
pattern is seen in panel B as circumferential LGE of the subendoca
inferior septal LGE in the midwall, is representative of the focal non
Table 2. CMR Examination Measures Calculated for the Study P
All Subjects
(n  24)
Infarct-Related L
(n  6)
Volumetric measures
Ejection fraction, % 48 15 45 10
EDVI, ml/m2 88 35 95 25
ESVI, ml/m2 49 29 53 22
LVM, g 182 81 158 67
LVMI, g/m2 100 52 87 25
LGE measures
LGE mass, g 31 45 18 14
LGE/LVM, % 15 18 10 6
*p  0.05 versus infarct-related and focal noninfarct LGE groups. Bonferroni me
was 6.
CMR  cardiovascular magnetic resonance; EDVI  end-diastolic volume inventricular mass index; other abbreviation as in Table 1.After 23 3 months of follow-up, 7 of 24 (29%)
f subjects have had hard cardiovascular events.
our subjects have died, 3 of whom had LGE (2
iffuse patterns and 1 focal pattern). Two patients
ith infarct-related LGE had nonfatal events: heart
lock requiring pacemaker placement and stroke.
ne subject without LGE had a resuscitated ven-
ricular fibrillation arrest and underwent coronary
rtery bypass grafting and implantable cardioverter-
efibrillator placement. Of note, 2 of 5 (40%) of
atients without any LGE have had events.
V global size and function. In the 24 patients,
jection fraction by CMR was 48  15%, end-
iastolic volume index was 88  35 ml/m2, end-
ystolic volume index was 49  29 ml/m2, LVM
as 182  81 g, and LVM index was 100  52
/m2 (Table 2). Average LGE mass was 31  45 g,
nd LGE constituted 15  18% of the LVM. The
GE mass correlated to LVM (r 0.44, p 0.03).
trend was noted toward a correlation between
GE mass and hemodialysis duration (p  0.11).
The ejection fraction was similar among all LGE
attern groups (Table 2). The LVM index was
in 3 Distinctive Patterns
inferior septum consistent with an infarct pattern. The diffuse
and midwall, sparing the subepicardium. Panel C, with its focal
rct LGE pattern. CMR  cardiovascular magnetic resonance.
lation and Presented by LGE Pattern Subgroups
Diffuse LGE
(n  7)
Focal Noninfarct LGE
(n  7)
No LGE
(n  5)
48 16 49 17 47 21
77 29 95 51 88 27
42 24 54 40 50 33
212 56 198 114 149 57
113 40 106 85 89 30
82 53* 8 7 0
37 16* 4 2 0
was used to adjust the multiple comparisons. The number of comparison here
ESVI  end-systolic volume index; LVM  left ventricular mass; LVMI  leftent
the
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GE
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454levated in all groups, but similar among groups.
or comparison purposes, normal values are 65  9
/m2 for men and 52  7 g/m2 for women (21).
he LGE mass as a percentage of LVM was 4 
% in the focal noninfarct LGE group, 10  6% in
he infarct-related, and 37  16% in the diffuse
GE group (p  0.05 vs. other 2 groups).
V regional function. In the entire cohort, end-
iastolic wall thickness was 10  3 mm, end-
ystolic thickness was 15  4 mm, absolute wall
hickening was 5  3 mm, and the percentage of
all thickening was 50  32%. When all segments
ere evaluated, an inverse relationship was found
etween the proportion of LGE per segment and
he percentage of wall thickening (p  0.0001).
hen infarct-related segments were excluded, as
nd-diastolic thickness increased, so did LGE (p 
.0001), and as LGE increased, the percentage of
all thickening decreased (p  0.0012).
I S C U S S I O N
hronic kidney failure portends a poor cardiovas-
ular prognosis. The first 3 years from the initiation
f hemodialysis brings the greatest risk of sudden
ardiac death (1). In the last decade, a 10% increase
n the mortality rate has been noted in the chronic
ialysis population (1). As stated by the U.S. Renal
ata System, “it is less clear how to identify
atients at risk for sudden cardiac death” (1).
yocardial fibrosis due to LVH may be such a
arker and LGE by CMR is a well-validated
echnique to identify myocardial fibrosis (11). Five
f the 7 patients with events during the 23-month
ollow-up had LGE. Unfortunately, due to the
oncern regarding gadolinium and NSF, further
tudies to define the relationship between LGE and
rognosis in this population will not be possible.
The location and distribution of LGE varies
ccording to the underlying pathophysiologic state.
ubendocardial or transmural LGE is most often a
onsequence of myocardial infarction (22). How-
ver, LGE is not exclusive to ischemic heart disease
nd can be seen in many cardiac conditions associ-
ted with myocardial fibrosis. Non-infarct-related
GE is often focal and present in the mid- or
ubepicardial myocardium in conditions such as
yocarditis (23), sarcoidosis (24), and idiopathic-
ilated (25) and hypertrophic cardiomyopathy (26).
Our investigation included 24 chronic hemodi-
lysis patients at high risk for cardiovascular events.
high proportion (79%) of this population hadGE and most cases were non-infarct-related. dark et al. (27) recently studied 134 end-stage
enal failure patients in Scotland. In their study,
nly 28% (38 of 134) had LGE, and those cases
ere evenly composed of subendocardial and diffuse
GE. The lower prevalence of LGE, even in the
ace of higher CAD prevalence (59% in the study
onducted by Mark et al. (27) vs. 50% in the present
tudy), is likely due to differences between the study
opulations. Although subject age was similar, he-
odialysis patients constituted only 69% of the
ohort of Mark et al. (27) and only 55% of the LGE
ositive group. Hemodialysis itself may in some
ay contribute to myocardial fibrosis. The current
tudy included a high proportion of African Amer-
cans, unlike the study conducted by Mark et al.
27), and this racial group may have a predisposition
o myocardial fibrosis. Diabetics composed only
4% of the population of Mark et al. (27) compared
ith 71% of the current study. Advanced glycosy-
ation end products in diabetes may also play a role
n myocardial fibrosis (28). Measured LVM was
imilar between the 2 studies. Although LGE mass
as only 9  5 g in the LGE-positive patients in
he study of Mark et al. (27) compared with 31 
5 g in the present study, the former study also
ound a significant relationship between LGE mass
nd LVM index (p  0.01).
Prior histologic studies may provide valuable
nsight into the potential meaning of the noninfarct
attern of LGE seen in the present study. Mall et
l. (29) conducted autopsies on 60 patients on
emodialysis for 6 months, excluding subjects
ith obstructive CAD. They demonstrated that up
o 91% of chronically uremic patients have diffuse
oncoronary intermyocardiocytic fibrosis of the LV
ree wall that correlates to hemodialysis duration
nd is not present in controls (29). They noted that
he fibrosis was not similar in appearance to that
ound in hypertension, myocarditis, or myocardial
nfarction. Mall et al. (29) were able to relate
ntermyocardiocytic fibrosis to diabetes and uremia,
ndependent of hemodialysis. The independent ef-
ect of diabetes mellitus may help explain the
iscrepancy between the prevalence of fibrosis dis-
overed as LGE in the present study and that of
ark et al. (27). At autopsy, Mall et al. (29)
stablished a relationship between the severity of
brosis and duration of dialysis. In our smaller
atient sample, we found a trend toward such a
elationship.
Circumferential, subendocardial LGE that does
ot correspond to coronary vascular beds has been
escribed in amyloidosis (30).The diffuse nonin-
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455arct pattern of LGE in the present study appears
imilar to that described in amyloidosis (30). Amy-
oidosis due to beta-2-microglobulin deposition is a
nown but rare complication of hemodialysis (31).
he true prevalence of dialysis-related amyloidosis
s unknown and thought to be decreasing with the
dvent and use of high flux dialyzing membranes
32). The presence of intermyocardiocytic fibrosis
n an autopsy study was not due to amyloidosis as
pecific histological staining (Congo red) failed to
dentify beta-2 microglobulin (29). Although his-
ological confirmation was not performed in the
resent study, the possibility of amyloidosis in the
atients with diffuse LGE remains.
A significant relationship was noted between
VH and LGE, and an inverse relationship was
ound between LGE and segmental LV dysfunc-
ion. The fibrosis or infiltrative disease identified by
GE likely contributes to the dysfunction associ-
ted with LVH. A similar relationship has been
emonstrated by Choudhury et al. (26) in hyper-
rophic cardiomyopathy. Left ventricular hypertro-
hy is present in 60% to 80% of patients upon
nitiation of dialysis (33) and has been shown to be
n independent predictor of cardiovascular events
4,34,35). Further investigation into the time course
nd risk factors underlying this process may prove
o be of clinical value.
imitations and clinical implications. Our study pop-
lation size is relatively small. Future studies will be
imited by concern regarding the potential link
etween gadolinium chelates and NSF in renal
ailure patients (5,6). In our small cohort of 24
ubjects, 1 new case of NSF was noted after 23  3
onths of follow-up in a patient who had receivedFoundation Task Force on Cardiovas-
ProHance, and Mu
ber 22, 2006.his disorder is unknown, but in high-risk individ-
als, it may be as high as 5% (7).
The lack of histologic correlation allows for only
peculation as to the etiology of the nonischemic
GE identified in this cohort. Although the num-
ers remain small and the follow-up is preliminary,
he presence of LGE did not appear to predict
vents (5 of 19 patients) in this population as events
ere equally or even more prevalent (2 of 5 patients)
n patients without LGE. However, LGE is known
o have prognostic value in a number of clinical
ettings, especially as it relates to risk of ventricular
rrhythmia (15,16).
O N C L U S I O N S
his study pertains to a chronic hemodialysis pop-
lation at high risk for cardiovascular events and
stablishes that LGE is prevalent and related to the
egree of LVH. The majority of LGE in this
opulation is not infarct-related and may represent
brosis due to LVH and/or an infiltrative process.
on-infarct-related LGE is more prevalent in hy-
ertrophied, dysfunctional LV segments. Hemodi-
lysis patients are at high risk for sudden cardiac
eath and although risk factors such as LVH have
een recognized, no mechanism or specific markers
ave been identified. The distribution and extent of
GE may be such a marker, although further
tudies using gadolinium chelates in this population
ill no longer be possible.
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